Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Democrats — including newly elected senators from deep-red states — are finding common ground in targeting corporate health care practices they blame for soaring costs. From breaking up insurer-PBM-pharmacy conglomerates to expanding Medicare drug price negotiations, the policy agenda is getting bolder. And surprisingly, a few Republicans may be on board too.
Democrats may be far from agreeing on Medicare for All, but they're increasingly united on one thing: going after Big Health Care. Newly elected senators from red states like Texas, South Carolina, and Kansas are championing policies — capping insurer profits, banning private equity-owned hospitals, expanding Medicare drug negotiations — that until recently were confined to left-leaning think tanks. The shift reflects a political reality: sweeping federal health care expansion isn't feasible under President Trump, but populist anti-corporate messaging can rally both the base and potentially some Republicans.
The momentum is building across party lines. Sen. Elizabeth Warren's Break Up Big Medicine Act has a Republican co-sponsor in Sen. Josh Hawley, and Rep. Morgan Griffith — the top GOP member on the House Energy and Commerce Health Subcommittee — openly expressed skepticism about insurer-PBM-pharmacy consolidation. Even prescription drug pricing, a Trump priority, could become a bipartisan deal point.
Key Takeaways:
Why it matters: Just four years ago, Democrats barely scraped together enough votes for modest drug price negotiations. Today, the political appetite for confronting health industry giants is significantly stronger — and the conversation is starting to cross the aisle.
